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Tumor Progression and Metastasis 
in Most Human Cancers
Guang-Jer Wu
Abstract
In addition to oncogenes and tumor suppressor genes, cell adhesion molecules 
(CAMs) also significantly contribute to tumor progression and metastasis. For the 
past two decades, we have demonstrated that METCAM/MUC18, a cell adhesion 
molecule in the immunoglobulin-like gene superfamily, orchestrates complex 
interactions of tumor cells with various stromal cells in the tumor microenvi-
ronment, resulting in augmentation or reduction of the metastatic potential of 
carcinoma cells. Here we show that METCAM/MUC18 plays a positive role in the 
tumor progression and metastasis in most human cancers, such as breast cancer, 
human melanoma and most mouse melanoma, nasopharyngeal carcinoma type III, 
prostate cancer LNCaP and DU145 cell lines, and perhaps angiosarcoma, gastric 
cancer, glioma, hepatocellular carcinoma, non-small cell lung adenocarcinoma, 
small cell lung cancer (SCLC), osteosarcoma, and human and mouse pancreatic 
cancer. Possible mechanisms in the METCAM/MUC18-mediated tumor progression 
and metastasis are proposed. Anti-METCAM/MUC18 antibodies and siRNAs may 
be used as therapeutic agents to treat these cancers.
Keywords: METCAM/MUC18, Ig-like CAM, tumor promotion, metastasis, breast 
cancer, melanoma, nasopharyngeal carcinoma, prostate cancer, many solid tumors, 
mouse models
1.  Introduction: cancer and CAM-mediated tumor progression and 
metastasis
Tumor/cancer is a chronic disease resulting from gradually accumulation of muta-
tions or epigenetic alterations in our genetic material, DNA [1]. Ten to twenty percent 
cancer risk comes from hereditary factors and 80–90% of cancer risk from environ-
mental factors [2]. The environmental factors in the physical containment include 
(a) chemically polluted drinking water, air and soil, and diet; (b) irradiation from 
solar UV, artificial sources, and environmental radioactive elements; (c) pathological 
agents (tumor viruses, bacteria, and parasites); and (d) the lifestyle (stress, chronic 
inflammation from obesity, and free radicals from metabolism) [3–5]. These agents 
aim to attack our DNA in the somatic cells resulting in slow accumulation of muta-
tions and epigenetic alterations in our genes throughout the life span [6]. The ques-
tion of “Is cancer a metabolic disease or a genetic disease?” cannot be easily answered. 
Prior to 1970, most cancer researchers thought cancer is a metabolic disease because 
of the Warburg effect. After 1970 when Warburg died and after 1971 when oncogenes 
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were discovered, most researchers shifted their thinking to view cancer as a genetic 
disease. After 2010–2015 when cancer was rediscovered as a metabolic disorder, the 
view was shifted back to “cancer is a metabolic disease.” While cancer as a genetic 
disease looks to be impossibly complex, tumor cells are a genetic “train wreck” with 
an infinite number of mutations and epigenetic alterations in ~250 oncogenes and 
~700 tumor suppressor genes. In contrast, cancer as a metabolic disease with only 
seven different “metabotypes” appears to be remarkably simple to deal with, since all 
the above mutations mainly affect three major metabolic pathways: aerobic glycolysis, 
glutaminolysis, and one-carbon metabolism [7].
Besides the traditional oncogenes and tumor suppressor genes [6], cell adhesion 
molecules (CAMs) also contribute directly to the tumor initiation and metastasis 
or orchestrate the tumor microenvironment to affect the tumor progression [8]. 
CAMs are involved in several biological functions, such as cellular social behaviors, 
tissue architecture, organ formation, blood vessel generation and angiogenesis, 
immune and inflammatory reactions, and wound healing [8]. An altered expression 
of CAMs has implications in tumor progression and metastasis, since most CAMs 
govern cellular social behaviors by directly contributing to cell adhesion, epithelial-
to-mesenchymal transition (EMT), and cross talk with the intracellular signal 
transduction pathways affecting other tumor progression-related processes [8]. As a 
consequence, the aberrant expression of CAMs is capable of changing mobility and 
invasiveness, influencing outlasting ability and proliferation of tumor cells, and 
altering new blood vessel formation [8]. It also affects distant organ dissemination 
of carcinoma cells, because CAMs orchestrate complex interactions of tumor cells 
with various stromal cells in the tumor microenvironment, resulting in augmenta-
tion or reduction of the spreading potential of carcinoma cells [8].
Effects of the aberrant expression of the following CAMs on tumorigenesis 
and malignant progression are better studied, such as cadherin [9], integrins [10], 
CD44 [11], CEACAM [12], mucins [13], L1CAM [14], EpCAM [15], ALCAM [16], 
and METCAM/MUC18 [17]. Over the past 25 years, our team investigated the role 
of METCAM/MUC18 in several types of tumors, such as melanoma and breast, 
nasopharyngeal, ovarian, and prostate cancers [17–37].
2. METCAM/MUC18: an immunoglobulin-like (Ig-like) CAM
METCAM/MUC18 was first demonstrated to be abundantly expressed on the 
cellular membrane of most malignant human melanomas and hence was named 
as MUC18 [38] and MCAM [37]. It has been implicated to play a pivotal role in the 
malignant progression of human melanoma and hence was named as Mel-CAM 
[39]. However, subsequent studies showed that METCAM/MUC18 was not found 
to be exclusively expressed in melanoma, and furthermore, it did not initiate 
the transformation of normal cutaneous melanocytes to melanoma [39]. Instead 
METCAM/MUC18 was also expressed in endothelial cells and other epithelial 
tumors, and it could initiate or promote the transformation of other epithelial 
cells into carcinomas [40]. Thus METCAM/MUC18 also bears other names, such 
as S-endo1, CD146, A32, or METCAM [40, 41]. Later METCAM/MUC18 was also 
found to act as a suppressor in tumorigenesis and metastasis in some cancer cell 
lines [17, 37, 40].
The human METCAM/MUC18 (huMETCAM/MUC18) is a cell adhesion 
molecule (CAM) belonging to the Ig-like gene superfamily. The METCAM/MUC18 
usually has an apparent molecular weight of 110–150,000 due to its high glycosyl-
ation in all cell types. The naked huMETCAM/MUC18 is a single-chain transmem-
brane protein of 65–72 kDa consisting of 646 amino acids with an extracellular 
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N-terminal domain of 558 amino acids, a transmembrane domain with 24 amino 
acids, and a cytoplasmic domain of 64 residues (Figure 1) [38, 42].
Figure 1 shows that the N-terminal extracellular domain of the protein is 
composed of a signal peptide sequence (SP) and five immunoglobulin-like 
domains and one X domain [37, 38, 40, 42]. The intracellular cytoplasmic domain 
has one, three, and one protein kinase consent sequences that are potentially to be 
phosphorylated by PKA, PKC, and CK2, respectively [37, 38, 40, 42]. The amino 
acid sequence of huMETCAM/MUC18 reveals nine potential N-glycosylation 
sites, of which six are conserved between human and mouse proteins, in the 
extracellular domain. METCAM/MUC18 is conserved in mouse, in which the 
amino acid sequences of mouse METCAM/MUC18 (moMETCAM/MUC18) are 
72.6% identical to the huMETCAM/MUC18 [43]. Therefore, both huMETCAM/
MUC18 and moMETCAM/MUC18 are capable of performing similar general 
functions of CAMs, such as controlling cellular social behaviors by impacting the 
adhesion status of cells and modulating signaling. Furthermore, overexpression 
of both human and mouse METCAM/MUC18s similarly affected tumor cells in 
in vitro motility and invasiveness, in vitro and in vivo tumorigenesis, and in vivo 
metastasis [42, 43].
The huMETCAM/MUC18 is expressed in at least ten normal tissues: hair fol-
licular cells, smooth muscle cells, endothelial cells, cerebellum, basal cells of the 
lung, activated T cells, intermediate trophoblasts [44], breast epithelium [18–19], 
nasopharyngeal epithelium [23], and ovarian epithelium [27]. The protein is also 
expressed in several carcinomas, such as breast carcinoma, intermediate tropho-
blast tumors, melanoma, prostate adenocarcinoma, osteosarcoma, and others 
[17, 44]. Our studies also indicate that overexpression of METCAM/MUC18 
augments tumorigenesis of breast carcinoma [18–20], nasopharyngeal carcinoma 
type III [24, 26], and prostate adenocarcinoma [34], but it does not have an obvi-
ous effect on tumorigenesis of most melanoma cell lines [21]. METCAM/MUC18 
overexpression also initiates the distant organ dissemination of prostate cancer 
[32–33] and augments the distant organ dissemination of melanoma [21] and 
breast carcinoma [45].
In contrast, overexpression of METCAM/MUC18 represses tumorigenesis 
of a mouse melanoma cell line, K1735-9 [22], nasopharyngeal carcinoma type 
I [24–25], and perhaps hemangiomas [46]. METCAM/MUC18 overexpression 
also represses the distant organ dissemination of the mouse melanoma cell line, 
K1735-9 [22]. Thus, METCAM/MUC18 plays a dual role in some of these cancers 
[17, 37].
Figure 1. 
The human METCAM/MUC18 (huMETCAM/MUC18). The figure represents the protein structure of 
huMETCAM/MUC18 with its three domains: (1) A large extracellular domain showing a signal peptide (SP), 
the five Ig-like variables (V1 and V2) and conserved (C1, C2, C2′, and C2″) domains, each of which held 
together by a disulfide bond, and one X domain; six conserved N-glycosylation sites indicated as wavy lines in V1, 
the interdomain C2′/C2″, C2″, and X domains. (2) A short transmembrane domain (TM). (3) A cytoplasmic 
domain containing five potential phosphorylation sites (P).
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3.  METCAM/MUC18: a promoter in tumor progression and metastasis 
of human cancers
The protein METCAM/MUC18 is expressed in breast cancer, melanoma, naso-
pharyngeal carcinoma, and prostate cancer and also expressed in others cancers, 
such as angiosarcoma, gestational trophoblastic tumors, Kaposi’s sarcoma, leiomyo-
sarcoma, some lung adenocarcinoma and squamous and small cell carcinomas, and 
some neuroblastomas [44]. However, its role in the progression of most of these 
cancers is not well known. Recent meta-analysis suggests that high METCAM/
MUC18 expression in many solid tumors appears to be associated with poor prog-
nosis and patient survival [47]. In addition, METCAM/MUC18 expression and its 
possible role in other solid tumors began to emerge, such as angiosarcoma, gastric 
cancer, hepatocellular carcinoma, glioma, non-small cell lung cancer (NSCLC), 
small cell lung cancer (SCLC), osteosarcoma, and pancreatic cancer, as described in 
the following.
3.1 Breast cancer
Breast carcinomas were heterogenous with three histological subtypes (ER+, PR+,  
and ERBB2 receptor (HER)) ([48] for a review), with at least five distinct molecular 
subtypes (luminal A (ER+ and PR+), luminal B (ER+ and PR±), basal-like (ER-, 
PR-, AR-), HER2-enriched (HER2+), and normal-like) [49], or with ten combined 
genomic/transcriptomic subtypes [50]. HuMETCAM/MUC18 was found to be 
expressed in breast cancer cell lines and tissues of basal-like and mesenchymal 
subtypes at much higher levels than in luminal subtypes, which poorly or very weakly 
expressed the protein [18, 51]. METCAM/MUC18 was suggested by two groups to 
play a tumor suppressor role [52, 53] but by two other groups as a tumor promoter 
in the progression of human breast cancer [51, 54]. To resolve this controversy, we 
started separate studies to explore the real role of METCAM/MUC18 in the tumor 
progression of human breast cancer. We demonstrated that ectopic expression of 
METCAM/MUC18 in two breast cancer cell lines (MCF-7 and SK-BR-3) augmented 
their ability in epithelial-to-mesenchymal transition (EMT) and formation of colony 
in vitro and increased tumor-take and tumorigenesis (in vivo tumorigenesis) in 
athymic nude mice [18–20].
Treatment with an anti-METCAM/MUC18 antibody decreased the motility and 
invasiveness of the two basal-like cell lines, MDA-MB-231 and MDA-MB-468, which 
endogenously express the protein [19]. Overexpression of huMETCAM/MUC18 
could also induce metastasis of the MCF7 cells in SCID/beige mice with the supple-
ment of estrogen [45]. Furthermore, enforced expression of METCAM/MUC18 
increases the metastasis of both basal-like cell lines in athymic nude mice [45]. 
The tumor suppression role of huMETCAM/MUC18 in tumorigenesis of human 
breast cancer cells previously observed by one group [52] has not been supported by 
evidence published later [18, 45]. The most likely reason may be due to the artifact 
of including fetal bovine serum in their injection mixtures, as extensively discussed 
in our published paper [18]. The other discrepancy may be because only in vitro 
experiments were done, but no in vivo animal test [51, 53, 54]. Taken together, 
METCAM/MUC18 plays a positive role in the tumor progression of four human 
breast cancer cell lines. From the results of further preliminary mechanical study, 
we suggest that METCAM/MUC18 promotes the progression of human breast 
cancer cells by increasing proliferation, angiogenesis, epithelial-to-mesenchymal 
transition (EMT), and switching to aerobic glycolysis [18–20]. METCAM/MUC18’s 
downstream signaling molecules may also be used as therapeutic targets for the 
treatment of breast cancer.
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3.2 Melanoma
Most malignant human melanomas overly expressed huMETCAM/MUC18 on the 
cellular surface, suggesting that it may promote the malignant progression of human 
melanoma [38]. This notion is supported by the evidence that enforced expression 
of the huMETCAM/MUC18 increases the metastatic ability of three nonmetastatic 
human melanoma cell lines in the immune-incomplete mouse models [55, 56]. It 
is further corroborated by our results that enforced expression of moMETCAM/
MUC18 also augments the lung nodule formation ability of two low-metastatic 
mouse melanoma cell lines, K1735-3 and K1735-10, in a syngeneic mouse model with 
the complete immunity [21]. However, overexpression of moMETCAM/MUC18 in 
K1735-3 and K1735-10 subline has a minimal effect on tumor formation.
METCAM/MUC18 enables melanoma cells to establish pulmonary metastasis 
only when the METCAM/MUC18-expressing melanoma cells are injected into the 
tail vein (experimental metastasis) [18–20, 55, 56], but not when the cells were 
injected subcutaneously (spontaneous metastasis) either in immune-deficient 
mouse models [55, 56] or in immune-competent syngeneic mouse models [21]. 
Thus, it bypassed the initial stages of metastasis, suggesting that METCAM/
MUC18 may promote melanoma metastasis only in the later stage of metastasis. 
This result is consistent with a later observation in that huMETCAM/MUC18 does 
not confer melanocytes the ability to initiate the tumor progression into melanoma 
[39]. Surprisingly when another mouse melanoma cell line, K1735-9, was used for 
the similar test in the syngeneic brown mouse model, a totally opposite result was 
obtained [22], to be described in Section 4. The exact reason for the dual role of 
METCAM/MUC18 in the tumor progression and metastasis is not clear, but one 
possibility is suggested in Section 5.
Taken together, our syngeneic mouse system should be more useful than the 
immune-incomplete mouse system to comprehend the complex mechanisms 
played by METCAM/MUC18 in the malignant progression of melanoma cells. 
Furthermore, the knowledge learned from our syngeneic mouse systems should 
also be useful for testing the real efficacy of various therapeutic strategies before 
the treatment of clinical melanoma, because they should more closely mimic the 
clinical melanoma cases than the xenograft models.
3.3 Nasopharyngeal carcinoma
Most (90%) nasopharyngeal carcinoma (NPC) occurs in the non-lymphomatous, 
squamous epithelial lining of the posterior nasopharynx [23, 24]. Three histologi-
cal subtypes of NPC are defined according to World Health Organization (WHO) 
classification: WHO type I (keratinizing squamous cell carcinomas), WHO type 
II (nonkeratinizing squamous cell carcinomas), and WHO type III (undifferenti-
ated carcinomas) [23, 24]. Epidemiological studies suggested three major risk 
factors, such as genetic predisposition, dietary and environmental factors, and the 
Epstein-Barr virus (EBV) infection, that may induce the unusual incidence of NPC 
in endemic areas [23–26]. However, the biological mechanisms of their contribution 
to tumor initiation, development, and malignant progression remain elusive. Since 
aberrant expression of CAMs, such as CD44, connexin 43, E-cadherin, and ICAM, 
has been associated with the progression of NPC ([23] for a review), it is highly 
probable that these risk factors may alter cell adhesion molecule (CAM) expression 
and lead to tumorigenesis and malignant progression of NPC. In order to test this 
hypothesis, we initiated the studies on the possible role of altered METCAM/MUC18 
expression in the malignant progression of nasopharyngeal carcinoma. First, we 
investigated if an aberrant expression of METCAM/MUC18 was associated with NPC 
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[23] and then the effect of METCAM/MUC18 overexpression on the tumorigenesis 
of two NPC cell lines in an athymic nude mouse model [24–26], as described next.
We used immunohistochemistry (IHC) method to determine the expression 
level of huMETCAM/MUC18 in 7 tissue specimens of normal nasopharynx and 97 
specimens of three different types of NPC and also used immunoblot method to 
determine several cell lines established from type I to type III NPC [23]. The results 
showed a weak expression of the METCAM/MUC18 protein in only 27% of the 
NPC tissues (no expression in 73% of the NPC tissues), in contrast to all the normal 
nasopharynx tissues which exhibited a high expression of the protein, suggesting 
that METCAM/MUC18 may play a tumor suppressor role in the development of 
NPC during the progression of cancer [23]. Then, we further tested the hypothesis 
by examining the effect of ectopic METCAM/MUC18 expression on in vitro cellular 
behavior and in vivo tumorigenesis of the two NPC cell lines in athymic nude mice. 
Indeed, the predicted hypothesis was supported by the results when NPC-TW01 
cells were used for the tests [24–26], as described in Section 4. Surprisingly, con-
trary to the hypothesis, when NPC-TW04 cell line was used for similar in vitro 
and in vivo tests, we observed that overexpression of METCAM/MUC18 actually 
promoted in vitro and in vivo tumor growth of NPC-TW04 cells [24, 26], which 
were established from type III NPC [57]. We thus conclude that METCAM/MUC18 
plays a positive role in the tumor progression of the type III NPC [24, 26]. Overall, 
METCAM/MUC18 plays a dual role in the tumor progression of NPC.
3.4 Prostate cancer
For the past two decades, we have first demonstrated that METCAM/MUC18 
expression in human tissues was associated with the progression of human prostate 
cancer [31] and also with that of mouse adenocarcinoma in a transgenic model, 
TRAMP [33]. We further showed that overexpression of METCAM/MUC18 
promotes the progression of a human prostate cancer cell line, LNCaP, which was 
established from lymph node lesions [32, 34], as described next.
First, by using IHC and immunoblot assays to determine the expression of 
huMETCAM/MUC18 in the tissues of human normal prostate gland, patients 
with BPH, and patients with prostate cancer and metastatic lesions, we found that 
METCAM/MUC18 was highly expressed in all of the high-grade PINs and most 
of prostate carcinoma at advanced pathological stages and metastatic lesions, but 
it was not expressed in most normal prostate glands and in all BPH lesions. Thus, 
huMETCAM/MUC18 expression is associated with the progression of human 
prostate cancer [31].
Second, by using similar immunological methods to determine the expression of 
moMETCAM/MUC18 in the prostatic tissues of a transgenic mouse model, TRAMP, 
at different times of life span, we found that moMETCAM/MUC18 expression was 
increased with the progression of the mouse adenocarcinoma in this transgenic 
mouse model. Thus, moMETCAM/MUC18 overexpression is associated with the 
progression of mouse prostate adenocarcinoma in a transgenic mouse model, 
TRAMP [33].
Third, we tested the effect of overexpression of huMETCAM/MUC18 in a 
human prostate cancer cell line LNCaP on its tumorigenesis when the cells were 
injected at the non-orthotopic SC sites in nude mice. We observed that huMETCAM/
MUC18 overexpression promoted the tumorigenesis of the cell line at the non-
orthotopic sites [34]. Then, we tested the effect of overexpression of huMETCAM/
MUC18 in the LNCaP cell line on its tumorigenesis and establishing metastatic 
lesions when the cells were injected at the orthotopic site (in the dorsal and lateral 
lobes of mouse prostate gland) in a male nude mouse model [32]. We found that 
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huMETCAM/MUC18 overexpression promoted the tumorigenesis at the orthotopic 
prostate gland and also initiates metastatic lesions at periaortic lymph nodes and 
multiple distant sites (such as seminal vesicles, ureters, and the kidney). From the 
results, we conclude that ectopic overexpression of huMETCAM/MUC18 promotes 
in vivo tumorigenesis of the cells at either at non-orthotopic SC sites or at ortho-
topic prostate gland and also that it also initiates metastasis of the cells to multiple 
distant sites when cells were injected at the orthotopic mouse prostate gland. Taken 
together, we concluded that huMETCAM/MUC18 expression promotes the tumor 
progression of LNCaP cells in an athymic nude mouse model [31–36].
Fourth, to check if the above conclusion is also extended to another human 
prostate cancer cell line, DU145, we recently tested the effect of knocking down the 
endogenously expressed METCAM/MUC18 on tumorigenesis in a nude mouse sys-
tem, since DU145 endogenously expresses a high level of METCAM/MUC18 [58]. We 
found that knocking down of the endogenously expressed METCAM/MUC18 with 
three shRNAs decreased the subcutaneous tumorigenesis in male nude mice in com-
parison to a control shRNA, as shown in Figure 2. We thus concluded that METCAM/
MUC18 expression in DU145 cell line, which was established from brain lesions, plays 
a positive role in tumorigenesis (and perhaps metastasis) similar to in LNCaP cells.
In summary, we conclude that METCAM/MUC18 plays a positive role in the 
tumor progression and metastasis of two human prostate cancer cell lines, LNCaP 
and DU145. However, we recently observed an opposite result when the third 
human prostate cancer cell line PC-3 was used for the similar test, as described in 
Section 4, suggesting that METCAM/MUC18 also plays a dual role in the tumor 
progression of human prostate cancer.
3.5 Other solid tumors
3.5.1 Angiosarcoma
METCAM/MUC18 very likely promotes the formation of angiosarcoma, as 
supported by our preliminary results as described next. MoMETCAM/MUC18 was 
expressed at a higher level in one angiosarcoma clone, SVR, which was transfected 
with H-Ras, than in the control cell line, MS-1, an immortalized normal endothelial 
cell line [59]. Furthermore, the tumorigenicity of the SVR cell line was higher than 
the control cell line, thus in direct association with the higher expression level of 
Figure 2. 
Tumorigenicity of four shRNA knockdown clones of DU145. Effect of METCAM/MUC18 expression on in vivo 
tumorigenicity (left) and final tumor weight (right). (Left) Average tumor volumes from 5 mice S.C. injected 
with each of the 46 (control), 72, 24, and 27 clones/cells, which were transfected with 4 corresponding shRNAs 
in pGIPZ vector, were plotted against time. (Right) Average final tumor weights from five mice S.C. injected 
with the same clones/cells and standard deviations were plotted at the end point of experiment. P values are 
shown in the figure by comparing the data to the control clone [58].
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moMETCAM/MUC18 [40, 59]. This suggests that METCAM/MUC18 very likely 
promotes the tumor progression of angiosarcoma [40, 59].
3.5.2 Gastric cancer
The expression of huMETCAM/MUC18 in gastric cancer was investigated to 
evaluate its clinical-pathological and prognostic significance [60]. The expression of 
huMETCAM/MUC18 and three EMT-related proteins (E-cadherin, β-catenin, and 
vimentin) was examined by IHC method in 144 gastric cancers. Forty-one percent of 
the gastric cancer specimens were positive for the huMETCAM/MUC18 expression. 
HuMETCAM/MUC18 was also correlated positively with lymph node involvement 
and a poor prognosis. Furthermore, the huMETCAM/MUC18 expression was directly 
correlated with the lost expression of the epithelial marker, E-cadherin, and the 
gained expression of the mesenchymal markers, nuclear β-catenin and vimentin, 
suggesting that huMETCAM/MUC18 promotes EMT and also tumor progression in 
gastric cancer. It is possibly used as an independent index for a poor prognosis in gas-
tric cancer and as a potential therapeutic target for patients with gastric cancers [60].
3.5.3 Glioblastoma
Glioblastoma multiforme (GBM) is the most common brain malignancy, 
accounting for more than 45% of all primary malignant brain tumors. YY146, an 
anti-METCAM/MUC18 monoclonal antibody, was created and radiolabeled for 
the noninvasive positron-emission tomography (PET) imaging of orthotopic GBM 
models. 64Cu-labeled YY146 was demonstrated to be preferentially accumulated in 
the U87MG xenografted tumors, which permitted the obtaining of high-contrast 
PET images of small tumor nodules (∼2 mm). Furthermore, tumor-take of glioblas-
toma in an orthotopic xenograft mouse model correlates with the expression level 
of METCAM/MUC18 in a highly specific manner. Furthermore, YY146 can mitigate 
the EMT of these U87MG cells. Moreover, using YY146 as the primary antibody for 
histological studies of the World Health Organization, grades I through IV primary 
gliomas showed that there was a positive correlation between METCAM/MUC18-
positive staining and high tumor grade, which concurred with the GBM data 
available in The Cancer Genome Atlas (TCGA). Taken together, METCAM/MUC18 
appears to promote the aggressive phenotypes and hence the tumor progression of 
glioblastoma U87MG cells [61].
3.5.4 Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) remains the fifth most common malignant 
cancer and as the third leading cause of cancer-related mortality [62]. High-
throughput flow cytometry (HT-FC) profiling was used to characterize the 
expression of METCAM/MUC18 in the tumor cells from 30 human HCC samples. 
Increased expression of METCAM/MUC18 expression was significantly increased 
in hepatocellular carcinoma (HCC) tumor tissues as compared with the matched 
adjacent normal liver tissues. The METCAM/MUC18+ cells purified from HCC 
tumors have significantly increased colony-forming capacity, consistent with the 
characteristics of the cancer stem cells or the tumor-initiating cells, which are 
considered to contribute to the pathogenesis of HCC [63]. The high expression 
of METCAM/MUC18 in HCC samples and in HCC cell lines isolated from HCC 
samples was also confirmed by RT-PCR and Western blot analyses [64]. The HCC 
cell lines, which stably expressed METCAM/MUC18, had been shown to promote 
EMT, IL8 upregulation, and STAT1 downregulation, suggesting that METCAM/
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MUC18 promotes tumor progression and metastasis and predicts poor prognosis of 
hepatocellular carcinoma [64].
3.5.5 Non-small cell lung cancer
Lung cancer is the cancer with the highest mortality rate in the world [62], and 
non-small cell lung cancer (NSCLC) is the cause for about 80% of all lung cancer. 
The frequency of occurrence of adenocarcinoma, which is one of the major histo-
logical subtypes of NSCLC, has recently increased [65]. Eighty-five specimens of 
NSCLC were immunohistochemically analyzed by using an anti-METCAM/MUC18 
monoclonal antibody (clone N1238) on an NSCLC tissue microarray, and the stain-
ing was semiquantitatively scored. METCAM/MUC18 has been shown to express 
in 51% of NSCLC, preferentially squamous cell carcinomas. Positive expression of 
METCAM/MUC18 has also been associated with a shorter survival of patients with 
adenocarcinomas and used to predict the poor overall survival in patients with lung 
adenocarcinomas [65, 66]. Another group also used IHC to show that METCAM/
MUC18 expression was more frequently detected in males than in females. The pos-
itive expression of METCAM/MUC18 was associated with a poorer 5-year overall 
survival rate according to the survival analysis, suggesting that METCAM/MUC18 
may be a useful marker for predicting poor prognosis in patients with NSCLC 
following complete resection [65]. The third group reported that METCAM/
MUC18 protein expression was found in 46.61% of squamous cell carcinomas and 
37.47% of adenocarcinomas. METCAM/MUC18 expression positively correlated 
with vimentin but inversely with E-cadherin, indicating a positive correlation with 
EMT. METCAM/MUC18 expression in surgically treated primary tumor NSCLC is 
clearly associated with lymph node metastasis and is a statistically significant prog-
nostic factor [67]. Consistent with the results and also supporting the conclusion 
described above, we also showed that METCAM/MUC18 is expressed in a lung type 
II alveolar epithelial cell carcinoma cell, A549, and highly expressed in an adeno-
carcinoma cell line, H838, in comparison with its no expression in an immortalized 
normal embryonic WI38 cell line [68], as shown in Figure 3.
Furthermore, the fourth group observed that METCAM/MUC18 expression 
mediates acquisition of cancer stemness and enhances tumor invasion and metas-
tasis in a mouse model [69–70]. High expression of METCAM/MUC18 correlates 
with intrapulmonary metastasis of NSCLC cells in a mouse model [69–70]. Taken 
Figure 3. 
Expression of METCAM/MUC18 in normal lung tissue (SV40-immortalized normal lung cells) (WI38, lane 2) 
and lung type II alveolar epithelial cell carcinoma cell (A549, lane 3) and lung primary adenocarcinoma (H838, 
lane 4) [From [68]].
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together, METCAM/MUC18 plays a positive role in the tumor progression and 
metastasis of NSCLC.
3.5.6 Small cell lung cancer
Small cell lung cancer (SCLC), a lung cancer subtype with an aggressive and 
highly metastatic nature, is the cause for about 10–20% of lung cancer incidence. The 
5-year survival rate is at 7%, still very gloomy because choices of systemic treatment 
for SCLC patients have not been much increased. SCLC is highly responsive to che-
motherapy at the start of treatment. Despite favorable responses to initial therapy, 
SCLC relapse occurs within a year exhibiting a multidrug-resistant phenotype, which 
eventually contributes strongly to poor prognosis. Through in-depth proteomic pro-
filing, METCAM/MUC18 was identified as a markedly upregulated surface receptor 
in chemoresistant SCLC cell lines that exhibited a mesenchymal phenotype as well 
as in chemoresistant patient-derived xenografts compared to matched treatment-
naïve tumors. METCAM/MUC18 knockdown in chemoresistant cells reduced cell 
proliferation and decreased the IC50 inhibitory concentration of chemotherapeutic 
drugs. METCAM/MUC18 was found to modulate sensitivity of SCLC cells to chemo-
therapeutic drugs through upregulation of MRP1/ABCC1 expression and of the PI3/
AKT pathway in a SOX2-dependent manner. Metabolomic profiling revealed that 
METCAM/MUC18 modulates lactate production in chemoresistant cells that exhibit 
a distinct metabolic phenotype characterized by low oxidative phosphorylation. 
METCAM/MUC18 may serve as a novel therapeutic target to overcome chemoresis-
tance in SCLC [71]. In summary, the above results point to the positive role played by 
METCAM/MUC18 in the tumor progression and metastasis of SCLC.
3.5.7 Osteosarcoma
Osteosarcoma is the most common primary malignant bone tumor in children. 
Clinically evident metastatic disease is present in 10–20% of patients at diagnosis. 
Despite advancements in multimodality treatment, 5-year survival rates are ~40–50% 
[72]. METCAM/MUC18 was widely expressed on both osteosarcoma and Ewing’s 
sarcoma cells. METCAM/MUC18 protein and RNA are highly expressed in osteosar-
coma cell lines (SaOS, MG-63, U-2OS), but not in normal osteoblast cells [72–73]. 
ABX-MA1, an anti-METCAM/MUC18 antibody, did not appear to inhibit the in vitro 
proliferation of osteosarcoma cells, and neither did it significantly inhibit the in vivo 
growth of KRIB human osteosarcoma cells in the tibias of nude mice. Nevertheless, 
after 1½ months, a noticeably fewer number of ABX-MA1-treated mice spontane-
ously developed pulmonary metastatic lesions than the control antibody-treated 
mice. Furthermore, ABX-MA1 reduced the in vitro invasiveness of osteosarcoma cells 
in the Matrigel-coated trans-well assay and disturbed the homotypic adhesion among 
osteosarcoma cells and the heterotypic interaction of them with vascular endothelial 
cells. Osteosarcoma is effectively treated with anti-METCAM/MUC18 monoclonal 
antibodies [73–74]. Taken together, METCAM/MUC18 plays a positive role in the 
metastasis of osteosarcoma [72–74].
3.5.8 Human and mouse pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is the cancer that has the fourth 
highest mortality rate in the western countries [62]. The 5-year survival rate of 
all PDAC patients is 6%. Since this tumor is highly aggressive, cancer incidence 
is almost equivalent to its mortality rate [62]. Most pancreatic cancer deaths are 
due to metastasis. Especially, the events of tumor spreading are heterogeneous, 
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thus limiting the therapeutic choices for patients at late stages. METCAM/MUC18 
expression in cancer cells is associated with a secretion of soluble METCAM/
MUC18 (sMETCAM/MUC18) that plays an active role in tumor development. 
For example, sMETCAM/MUC18 causes the overproduction of its binding part-
ner, angiomotin, in cancer cells and endothelial cells in the tumor micro-milieu, 
Tumor/cancer tissues or cell lines Tumorigenesis Metastasis References
Angiosarcoma human cell lines MS1, SVR Increasing Not determined [40, 59]
Human breast cancer cell line MCF-7 Promotion Not determined [18]
Human breast cancer cell line SK-BR-3 Promotion Not determined [19, 20]
Human breast cancer cell lines 
MDA-MB-231 and MDA-MB-468
Promotion Promotion [19, 45]
Gastric cancer human tissues Promotion Not determined [60]
Glioma cell lines U87MG, U251 Promotion Not Determined [61]
Hepatocellular carcinoma human cell lines 
PLC/PRF/5, Huh7, MHCC97H and 97L 
HepG2, SMMC-7721, FOCUS, YY-8103, 
LM3, HLF, and primary HCC cell lines; 
normal liver cell line LO2
Promotion Not determined [63, 64]
Non-small cell lung cancer human cell 
lines A549, H23, H358, H460, H522, H838, 
HCC4006, H1650/ER, PC-9, and PC9GR 
and adenocarcinoma tissues
Promotion Promotion [65–70]
Small cell lung cancer human cell lines 
H69, H69AR, H82, H196, H209, DMS79
Promotion Not determined [71]
Clinical melanoma tissues and human 
melanoma cell lines SB-2, SK, XP-44
No effect Increasing and 
affecting the late 
stage
[38, 55, 56]
Mouse melanoma cell lines K1735-3, 
K1735-10
No effect 
or slight 
suppression
Increasing and 
affecting the late 
stage
[21]
Nasopharyngeal carcinoma type III human 
cell line NPC-TW04
Promotion Not determined [24, 26]
Osteosarcoma human cell lines CR9, 
MNNG-HOS, OHS, KPDX, KRIB, MG-63, 
shYY1, SaOS, SaOS-2, TE85, U20S
Promotion Augmentation [72–74]
Pancreatic cancer human cell lines and 
mouse cell lines ptf1a, LSL-Kras, LSL-
Trp53, Pdx1
Promotion Possible 
augmentation
[75, 76]
Clinical prostate cancer human tissues Increasing Increasing and 
affecting initiation 
in the early stage 
(PIN)
[31]
Human prostate cancer cell line LNCaP Increasing Increasing and 
affecting initiation 
in the early stage
[32, 34–36]
Human prostate cancer cell line DU145 Increasing Not determined [58]
Prostate adenocarcinoma in TRAMP mice Increasing Increasing and 
affecting initiation 
in the early stage
[33]
Table 1. 
The positive role of METCAM/MUC18 in the tumor progression of various solid tumors/cancers.
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which augments angiogenesis and proliferation and survival of cancer cells. These 
are mediated in part by the promotion and activation of c-myc in cancer cells. 
Dispensation of a new specific monoclonal antibody pinpointing on sMETCAM/
MUC18 represses tumor angiogenesis and growth of huMETCAM/MUC18+ pan-
creatic cancer cell xenografts in mice models. Taken together, sMETCAM/MUC18 
secreted by METCAM/MUC18+ tumors exhibit promoting effects on tumor 
angiogenesis and growth. Thus, an antibody pinpointing on sMETCAM/MUC18 
successfully represses vascularization, growth, and survival of METCAM/MUC18-
positive pancreatic tumors [75].
The expression of a homeodomain transcription factor MEIS1 (myeloid 
ecotropic viral integration site) has been associated with a ductal phenotype in 
pancreatic tissue architecture. To investigate a possible role of MEIS1 in the malig-
nant progression of PDAC, pancreatic cancer cell clones/lines, which overexpress 
MEIS1, were generated and tested for in vitro proliferation rate and motility. 
Overexpression of MEIS1 had no effect on in vitro proliferation rate but augmented 
motility. Furthermore, an upregulation of the MTCAM/MUC18 gene in the migrat-
ing cells has been found in the subsequent expression analysis. The interaction of 
MEIS1 with the enhancer DNA of METCAM/MUC18 is revealed by employing 
DNA pulldown and chromatin immunoprecipitation (ChIP) assay. Furthermore, 
the transcriptional activation of METCAM/MUC18 also facilitates migration of 
pancreatic cancer cells in vitro. Activation of METCAM/MUC18 through MEIS1 
occurs in a cell type-dependent fashion, reflecting the different routes that lead 
to metastasis in vivo. Thus, the transcription factor MEIS1 activates METCAM/
MUC18 expression to promote migration of mouse pancreatic tumor cell lines [76].
In summary, the positive role played by the METCAM/MUC18 in the progres-
sion of solid tumors has been extended from breast cancer, human and mouse 
melanoma, and prostate cancer to angiosarcoma [40, 59], gastric cancer [60], 
glioblastoma [61], hepatocellular carcinoma [63, 64], non-small cell lung adeno-
carcinoma [65–70], small cell lung cancer [71], osteosarcoma [72–74], human and 
mouse pancreatic cancer [75, 76], and prostate cancer [32–36, 58]. Taken together, 
METCAM/MCU18 appears to be more prevalently playing a positive role than a 
negative role in the tumor formation and/or cancer metastasis of various tumors/
cancers. Table 1 summarizes the positive role of METCAM/MUC18 in the tumor 
progression of many solid tumors/cancers.
4.  METCAM/MUC18: a tumor suppressor and metastasis suppressor in 
some cancers
In contrast to the positive role played by METCAM/MUC18 in the above cancers, 
recent results of testing the effects of METCAM/MUC18 expression on tumori-
genesis of other cancer types revealed that it also plays a negative role in the tumor 
progression and metastasis in some cancers, such as colorectal cancer, hemangioma, 
one mouse melanoma cell line K1735-9, NPC type I, ovarian cancer, human pancre-
atic cancer, and one human prostate cancer cell line PC-3, as described next.
4.1 Colorectal cancer
Colorectal cancer (CRC) is the third leading cause of cancer deaths in recent 
years [62]. Cancer stemness contributes to carcinogenesis, tumor relapse, and 
chemoresistance in traditional cancer therapeutics ([77] for a review). Stemness, 
which is the cell state with the properties of self-renewal, differentiation, and 
tumor-initiating potential, might be characterized by a set of more dynamic features 
13
METCAM/MUC18 Promotes Tumor Progression and Metastasis in Most Human Cancers
DOI: http://dx.doi.org/10.5772/intechopen.87037
influenced by the nature of the microenvironment. Various extrinsic cues and intrin-
sic signaling pathways, such as Wnt, Notch, and Hedgehog signals, are involved in 
the maintenance of stemness. Since METCAM/MUC18 has also been identified as 
a pluripotent marker for mesenchymal stem cells (MSCs), it was also hypothesized 
to exert potential effects on cancer cell stemness. One group of investigators has 
provided evidence to demonstrate that reduced expression of METCAM/MUC18 
actually functions as a positive regulator of stem cell properties in colorectal cancer 
through augmenting the Wnt/β-catenin signaling pathway. METCAM/MUC18 may 
actually manifest multifaceted effects on tumor progression in a context-dependent 
manner. The above evidence suggests that METCAM/MUC18 expression suppresses 
the tumor progression and metastasis of colorectal cancer [77].
4.2 Hemangioma
The expression of METCAM/M/MUC18 in hemangioma is inversely propor-
tional to the progression of hemangioma, suggesting that METCAM/MUC18 plays a 
negative role in the progression of hemangioma [46].
4.3 Mouse melanoma
As shown in the above section, moMETCAM/MUC18 does not have an obvious 
effect on the tumorigenesis of the two K1735 cell lines, such as K1735-3 and K1735-
10 [21]. In contrast, moMETCAM/MUC18 definitely acts as a tumor suppressor 
for the K1735-9 cell line. Overexpression of moMETCAM/MUC18 in K1735-9 also 
completely suppressed lung nodule formation in immunocompetent syngeneic 
C3H brown mouse model [22]. Thus, METCAM/MUC18 expression suppresses the 
tumor progression and metastasis of the mouse melanoma K1735-9 cell line [22].
4.4 Nasopharyngeal carcinoma (NPC)
According to the IHC results as shown in the above section, we suggested a 
hypothesis that METCAM/MUC18 may play a tumor suppressor function in the 
development of NPC during the progression of the cancer [23]. Then, we further 
tested the hypothesis by examining the effect of METCAM/MUC18 overexpression 
on in vitro cellular behavior and in vivo tumorigenesis of the two NPC cell lines 
in athymic nude mice. When the METCAM/MUC18-overexpressing NPC-TW01 
clones/cells, which were established from NPC type I, were used for the animal test, 
indeed tumor suppression was observed [24, 25]. However, the opposite results were 
obtained when the METCAM/MUC18-overexpressing NPC-TW04 clones/cells, 
which were established from NPC type III, were used for the similar tests. Thus, 
METCAM/MUC18 plays a dual role in the tumor progression of NPC [23, 24–26].
4.5 Ovarian cancer
Two independent groups showed that METCAM/MUC18 expression is corre-
lated with the progression of ovarian cancer [27, 78] and it affects in vitro behaviors 
of ovarian carcinoma cells [79]; however, the role of METCAM/MUC18 in the 
progression of epithelial ovarian cancer has not been directly tested in animal 
models. For this purpose, we initiated testing the effect of METCAM/MUC18 
overexpression on the in vitro cellular behaviors and in vivo tumorigenesis and 
malignant progression of human ovarian cancer cell lines in nude mice. First, we 
used a human ovarian cell line, SK-OV-3, for the in vitro and in vivo tests. We 
observed that overexpression of METCAM/MUC18 reduced in vitro motility and 
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invasiveness [28] and suppressed in vivo tumorigenesis on subcutaneous (SC) 
sites and in intraperitoneal cavity as well as in vivo malignant progression of the 
human ovarian cancer cell line SK-OV-3 in intraperitoneal (IP) cavity in female 
athymic nude mice [28]. When the other human ovarian cancer cell line, BG-1, was 
similarly tested, similar results were also observed [80]. In summary, we supplied 
in vitro and in vivo evidence to definitely support the conclusion that METCAM/
MUC18 plays a suppressor role in the tumorigenesis and malignant progression of 
two human ovarian cancer cell lines [28–30, 80], suggesting that METCAM/MUC18 
is a strong candidate as a new tumor and metastasis suppressor in human ovarian 
cancer cells.
4.6 Human pancreatic cancer
In contrast to the above results of human and mouse pancreatic cancer that 
METCAM/MUC18 expression plays a positive role in the malignant progres-
sion of PDAC, a group has demonstrated that METCAM/MUC18 expression in 
cancer-associated fibroblasts (CAFs) has been correlated with the pre-pancreatic 
intraepithelial neoplasia (PIN) and the invasive ductal pancreatic cancer with a low 
histological grade. Furthermore, the prognosis for the patients with a low METCAM/
MUC18 expression is poorer than those with a high METCAM/MUC18 expression. 
Suppressing METCAM/MUC18 expression in CAFs augmented tumor cell in vitro 
motility and invasiveness in a co-culture system that includes both tumor cells and 
CAFs. Knockdown of METCAM/MUC18 also augmented CAF activation, pos-
sibly via regulation of NF-kB activity, which in turn induces the yield of factors for 
tumorigenesis. In line with this notion, METCAM/MUC18 overexpression in CAFs 
decreased in vitro motility and invasiveness of the cancer cells co-cultured with 
CAFs. Moreover, METCAM/MUC18 expression in CAFs was decreased by interac-
tion with cancer cells. Taken together, reduced METCAM/MUC18 expression in 
CAFs and reduction of METCAM/MUC18 augment tumor progression of pancreatic 
cancer [81]. Therefore, METCAM/MUC18 expression suppresses the tumor progres-
sion and metastasis of pancreatic cancer. In comparison with the results from Section 
3.5.8, METCAM/MUC18 expression also plays a dual role in pancreatic cancer.
4.7 Prostate cancer
We recently used the knocking down strategy similar to that of DU145 cell 
line to test the effect of decreased endogenous METCAM/MUC18 expression on 
in vivo tumorigenesis of another human prostate cancer cell line, PC-3, which 
was established from bone lesions. Surprisingly we found that knocking down the 
endogenously expressed METCAM/MUC18 increased the tumor proliferation of 
PC-3 cells, suggesting that expression of METCAM/MUC18 suppressed the tumori-
genesis of the human prostate cancer cell line PC-3 [82]. We thus conclude that 
METCAM/MUC18 serves as a tumor suppressor in the PC-3 cell line. Thus, similar 
to mouse melanoma, NPC, and pancreatic cancer, METCAM/MUC18 expression 
also plays a dual role in tumor progression and metastasis in human prostate cancer.
In summary, METCAM/MUC18 may also suppress tumor progression and 
metastasis of the following solid tumors, such as colorectal cancer [77], mouse 
melanoma K1735-9 subline [22], NPC type I [24, 25], ovarian cancer [28–30], 
human pancreatic cancer [81], one prostate cancer cell line PC-3 [82], and perhaps 
hemangioma [46]. Thus, METCAM/MUC18 appears to play a negative role in 
tumor progression and metastasis of some solid tumors but a dual role in some 
other solid tumors. It is not clear why METCAM/MUC18 plays a dual role. Since 
METCAM/MUC18 only plays a dual role in different cell lines from the same type 
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of cancer or in different type of cancers, but never in the same cancer cell line, it is 
logical to suggest a possible explanation that the intrinsic properties of each cancer 
cell line may provide specific co-factors or heterophilic ligands that may positively 
or negatively modulate the METCAM/MUC18-mediated tumorigenesis and metas-
tasis. This can be readily scrutinized by identifying these specific intrinsic cofactors 
or heterophilic ligands by using immunological coprecipitation method in the 
future studies, which is feasible as described in Section 5.5.
5. Preliminary and possible mechanisms
Since the huMETCAM/MUC18 was first discovered in the 1980s, three groups have 
worked on the role of huMETCAM/MUC18 in melanoma metastasis [38, 39, 55, 56], 
another group on the role of huMETCAM/MUC18 in the biology of endothelial cells 
[41, 83], and one group on breast cancer [45], and our group joined in the effort to 
study the role of huMETCAM/MUC18 in the progression of mouse melanoma [43] and 
prostate cancer [31–36] and later breast cancer [18–20], ovarian cancer [27–30], and 
NPC [23–26], as described above. Recently, more research groups have participated 
in further exploring the possible role of METCAM/MUC18 in other solid tumors in 
different organs, such as the colorectum [77], gastro-organ [60], glial cells [61], liver 
[63, 64], lung [65–71], bone [72–74], and pancreas [75, 76, 81]. Furthermore, prelimi-
nary work in leiomyosarcoma, esophagus squamous cell carcinoma, clear cell renal sar-
coma, and gallbladder adenocarcinoma are also beginning to emerge [47]. Thus, after 
decades of group effort, we are beginning to understand the biology of METCAM/
MUC18-mediated tumor progression.
However, we still know very little how METCAM/MUC18 mediates or regulates 
tumor progression and metastasis of cancer cells. Thus, the biological mechanisms 
describing the role of METCAM/MUC18 in tumorigenesis and malignant progression 
are still not well clarified. By deducing knowledge learned from the tumorigenesis of 
other tumors [6, 17, 37, 40] and angiogenesis [41, 83], we may be able to find some 
common clues to begin understanding its mechanisms. As such, the following five 
important aspects are much needed for immediate future studies, such as differential 
regulation at the transcription level in tumors of different organs; different signal-
ing pathways involved; contributions of different domains of the protein; possible 
different extent of N-glycosylation in different cancer cell lines, which may critically 
modulate the function of METCAM/MUC18 in tumor progression; and different 
kinds or quantities of cofactors or heterophilic ligand(s) in different cancer cell lines.
5.1 Transcriptional regulation
The mechanism of transcriptional control of METCAM/MUC18 gene is 
minimally studied [17]. So far, only 900 bp of the core promoter region of the 
huMETCAM/MUC18 gene are sequenced [84]. The core promoter reflects a typi-
cal housekeeping gene, which is rich in GC sequences but does not contain a TATA 
box. Nevertheless, it includes many consensus sequences presumably as putative 
binding sites for various transcription regulatory factors, such as SP-1, CREB [85], 
AP-2 [86–87], c-Myb [88], N-Oct2 (Brn2) [89], Ets [90], CArG [91], and Egr-1 
[92], and three insulin-responsive elements (one Ets and two E-box motifs) [93], 
suggesting that transcriptional control of the huMETCAM/MUC18 gene is regulated 
by various growth signals [37, 40]. For example, the huMETCAM/MUC18 gene is 
positively regulated by PKA/CREB (cAMP-responsive element binding protein) and 
negatively regulated by AP-2α [94]. Having a longer DNA containing sequences for 
tissue-specific expression of the gene is essential for further understanding the roles 
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of other regulators [17]. In line with this hypothesis, recently, the Ets sequence in the 
10 kilo-bp upstream region has been shown to regulate the expression of huMET-
CAM/MUC18 gene [95]. We have also engaged in this task by screening in a phage 
library containing the human genomic sequences and obtained several phage clones 
which contain at least 4 kilo-bp of in the upstream region of the promoter region of 
the gene for future studies [96]. Thus, the regulatory mechanism of tissue-specific 
expression of the METCAMMUC18 gene may be forthcoming.
The epigenetic control of the expression of huMETCAM/MUC18 gene has 
been implicated in human cancers, because huMETCAM/MUC18 gene is located 
at the locus of human chromosome 11q23.3 [97] that has been shown to be 
hypermethylated in NPC [98], suggesting that the expression of this gene may be 
regulated by epigenetic controls. To support this notion, our preliminary results 
of treating NPC cell lines with 5-Aza-2′-deoxycytidine (Aza-C) showed that after 
the treatment with Aza-C, METCAM/MUC18 expression was somewhat elevated 
in the NPC-TW01 cell line, but not in the NPC-TW04 cell line [99]. METCAM/
MUC18 has also been shown to be methylated in the early stage of most prostate 
cancer [100]. Thus, it is highly possible that the gene is epigenetically controlled 
in other cancers.
5.2 Signaling pathways
The cytoplasmic tail of huMETCAM/MUC18 contains consensus sequences 
potentially to be phosphorylated by PKA, PKC, and CK2, suggesting that its func-
tions may be mediated by these protein kinases and regulated by cross talk with 
various signaling pathways [17, 37, 38, 40, 42]. First, it is necessary to biochemi-
cally prove how many sites are actually phosphorylated in the cytoplasmic tail of 
the METCAM/MUC18 protein purified from different cancer cell lines and which 
protein kinase is responsible for the phosphorylation. After this is answered, then 
we can further study how METCAM/MUC18 mediates cross talk and networking 
with different signal pathways and is to be compared with the cytoplasmic tails 
of other CAMs [6, 8, 41]. Knowledge learned from the impact of other CAMs on 
tumor progression suggests that METCAM/MUC18, as an integral membrane 
Ig-like CAM, should mediate inside-in, inside-out, and outside-in signals to 
participate in intercellular communication and interaction of cell with the extra-
cellular matrix, which results in impacting EMT [6, 8, 41, 101]. Furthermore, 
huMETCAM/MUC18 has been shown to express in normal mesenchymal cells 
(smooth muscle, endothelium, and Schwann cells) in the tissue stroma and be 
a marker for the mesenchymal stem cells [102]; thus, expression of METCAM/
MUC18 may augment the EMT of cancer cells and hence the progression of many 
cancers. Moreover, METCAM/MUC18 may affect cancer cell progression by cross 
talk with signaling pathways that affect apoptosis, survival and proliferation, 
angiogenesis, and energy metabolism of tumor cells [6, 8, 101]. This is indeed 
found in our preliminary mechanical studies in breast cancer [19, 20], melanoma 
[21, 22], NPC [24–26], ovarian cancer [28–30], and prostate cancer [34–37]. 
Further systematic studies by using specific RNAi’s to knockdown the downstream 
effectors one by one in the METCAM/MUC18-expressing clones may be necessary 
to further understand this aspect of mechanism. Moreover, its interaction with 
cofactors or cognate heterophilic ligand(s) may alter these signals, which in turn 
should affect intrinsic tumor proliferation or impact tumor angiogenesis and/or 
mediate targeting to specific organs and promoting metastasis. Finally, METCAM/
MUC18 may interact with various hormonal receptors, growth or anti-growth 
factors/receptors, various chemokines/receptors, and the Ca++-mediated signaling 
members and affect tumor progression [17].
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HuMETCAM/MUC18 expression in melanoma cells is reciprocally regulated by 
AKT, in which AKT upregulates the level huMETCAM/MUC18 and overexpression of 
huMETCAM/MUC18 activates endogenous AKT, which in turn inhibits apoptosis and 
increases survival ability [103]. A similar mechanism is also likely to be used in other 
cancers; however, the detailed mechanism of how AKT upregulates the expression 
of METCAM/MUC18 in most cancers has not been reported. After the cytoplasmic 
tail is phosphorylated, then it may facilitate its interaction with FAK, thus promoting 
cytoskeleton remodeling, which in turn augments tumor cell motility and invasive-
ness [83]. Alternatively, after phosphorylation, huMETCAM/MUC18 may interact 
with the downstream effectors of Ras, activating ERK and JNK, which in turn may 
transcriptionally activate the expression of AKT or other genes that promote the pro-
liferation and angiogenesis of tumor cells. Moreover, by predicting from the relatively 
less selectivity of CK2 for its substrate and many CAMs which are phosphorylated by 
CK2, such as CD44, E-cadherin, and L1-CAM, and one of the integrin receptors in 
the extracellular matrix protein, vitronectin [104], huMETCAM/MUC18 is very likely 
to be phosphorylated by CK2 and linked to AKT to affect the proliferation, survival, 
and other tumorigenesis-related functions [105]. Recent findings appear to support 
this mechanism in that METCAM/MUC18 may promote EMT of breast cancer cells 
via activation of RhoA and upregulation of slug [45]. HuMETCAM/MUC18 may play 
an important role in regulating tumor dormancy or awakening, driving or preventing 
cancer cells to pre-metastatic niche, and formatting a microenvironment for favorable 
or unfavorable tumor growth in secondary sites [17, 37].
HuMETCAM/MUC18 may mediate hematogenous spreading of melanoma cells, 
as implicated by its expression in endothelial cells and malignant melanoma cells 
[106] and presence in junctions of endothelial cells [107, 108], essential for tumor 
angiogenesis in three tumor cell lines [109] and human prostate cancer LNCaP cells 
[110], and it is highly likely for that in other cancers [111, 112]. HuMETCAM/MUC18 
may also be implicated in promoting lymphatic metastasis of cancer cells, since it is 
one of the lymphatic metastasis-associated genes, which are upregulated in malig-
nant mouse hepatocellular carcinoma [113]. However, the detailed mechanisms of 
huMETCAM/MUC18-mediated hematogenous and lymphatic spreading of cancer 
cells remain to be investigated. For this purpose, labeling cells with viable dyes and 
employing a newly developed non-intruding, but highly photo-penetrating imaging 
photoacoustic tomography (PAT) to monitor each step of the process in real time in 
hairless nude mice may be helpful to provide some answers [114].
HuMETCAM/MUC18 may interact with the host immune system and affect 
tumor progression, though the immune system may have a contradictory role in 
the process [115]. This notion is positively supported by a recent finding that a 
subset of host B lymphocytes may be implicated in regulating melanoma malig-
nant progression via interaction with huMETCAM/MUC18 [116]. Our syngeneic 
mouse system for mouse melanoma should be useful for exploring the role of 
immune T and B cells in the progression of METCAM/MUC18-expressing mela-
noma cells. However, the role of B and T cells in the progression of most human 
cancer cells may not be explored in the athymic nude mouse models since most 
human cancer cells can only grow as xenografts in these immunodeficient mouse 
models. Nevertheless, to investigate the effect of huMETCAM/MUC18 expression 
on mediating NK cells in metastasis may be possible in these nude mouse models, 
which can be tested by pretreatment of nude mice with anti-NK surface marker 
antibodies to deplete the NK cells prior to injection of the huMETCAM/MUC18-
expressing cancer cells. This possibility is supported by the finding that the surface 
huMETCAM/MUC18 expressed in cancer cells may have a homophilic interaction 
with the NK cells, which also express huMETCAM/MUC18 and enhance cytotoxic 
functions of NK cells [117].
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5.3 Functional domain
To begin addressing the relation of the protein structure of huMETCAM/MUC18 to 
its functions in tumorigenesis and metastasis, we have generated mutant-deleted dif-
ferent domains of huMETCAM/MUC18 by using a special PCR method [118] and used 
them to determine their contribution to tumorigenesis. Surprisingly, our preliminary 
results showed that the ecto-domain and the intact copy of huMETCAM/MUC18 cDNA 
equally efficiently induced tumorigenesis in LNCaP cells in nude mice, suggesting the 
key role of the ecto-domain in inducing tumorigenesis of prostate cancer cells in vivo. 
However, this stirs up a puzzling question that the cytoplasmic domain was not essential 
for this process [119]. Nevertheless, critical direct test of using only the cytoplasmic 
domain for inducing tumor should be performed. It is essential that a systematic study 
has also to be performed in other cancer cell lines before a definitive conclusion can be 
drawn.
5.4 Glycosylation
Malignant progression of cancer cells has been shown to associate with an 
abnormal glycosylation, resulting in expression of altered carbohydrate deter-
minants [120]. Thus, the glycosylated status of huMETCAM/MUC18 in different 
cancer types may be different from normal cells and may manifest either a positive 
or negative effect on the progression of different cancer types, which should be very 
intriguing since huMETCAM/MUC18 possesses six conserved N-glycosylation sites 
in the extracellular domain [17, 37, 40].
Glycosylation of a protein may affect the proper folding, stability, and/or activity 
of a protein [121]. Both huMETCAM/MUC18 and moMETCAM/MUC18 are very 
likely heavily glycosylated, sialylated, and/or posttranslationally modified, because 
both have an apparent molecular weight of about 110–150 kDa, in comparison with 
the naked protein with a molecular weight of about 65–70 kDa [122]. The possible 
roles of METCAM/MUC18 glycosylation in inducing/promoting or suppressing the 
metastasis of cancer cells should be explored [123]. To initiate the study, we sub-
jected the huMETCAM/MUC18, which was isolated from one human cancer cell line, 
to the digestion with N-glycosidase F, neuraminidase (sialidase), O-glycosidase, or 
endoglycosidase H. We observed that the apparent molecular weight of the protein 
was decreased after digestion with N-glycosidase F and neuraminidase (sialidase), 
but not with O-glycosidase or endoglycosidase H [37, 40], suggesting that both sialic 
acid and N-glycans are probably the major carbohydrate side chains of huMETCAM/
MUC18. It is also possible that glycosylation may differ depending on the type of 
cancers. Thus, we suggested that different N-glycans at the N-glycosylation sites of 
huMETCAM/MUC18 may differ in different cancer cell lines, which may have signif-
icant positive or negative impacts on their EMT abilities as well as tumorigenesis and 
metastasis. Our hypothesis is supported by a recent report that described GCNT3 
as an upstream regulator of METCAM/MUC18 in that it glycosylates METCAM/
MUC18 and extends its half-life which results in further elevation of S100A8/
A9-mediated cellular motility in melanoma cells [124]. The role of glycosylation in 
the six N-glycosylation sites should be genetically altered to explore their effects on 
the functions of METCAM/MUC18 in tumor progression and metastasis.
5.5  Heterophilic ligands and cofactors that modulate the function of  
METCAM/MUC18
Since METCAM/MUC18 only plays a dual role in different cell lines from the same 
type of cancer or in different types of cancers, but never in the same cancer cell line, it 
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is logical to suggest a possible explanation that the intrinsic properties of each cancer 
cell line may provide specific cofactors or heterophilic ligands that may positively or 
negatively modulate the METCAM/MUC18-mediated tumor progression and metas-
tasis. This can be readily scrutinized by identifying these specific intrinsic cofactors or 
heterophilic ligands in different cancer cell lines by using immunological coprecipita-
tion method. This approach appears to be feasible as shown in our preliminary result 
in that a putative heterophilic ligand, 72 kDa protein, is identified [17, 37, 40]. This 
protein is present at a higher concentration in PC-3 cells than in DU145 that may be 
responsible for an opposite role of METCAM/MUC18 in tumor progression of these 
two cell lines. Thus, it is possible that mechanisms of huMETCAM/MUC18-mediated 
cancer progression may be different in different cancer cell lines due to their different 
intrinsic properties, which possess different concentration or completely different 
heterophilic different ligands and/or cofactors. The heterophilic ligands and/or cofac-
tors of METCAM/MUC18 may contribute to the cellular intrinsic properties, such 
as adhesion-associated signaling cascades and cytoskeleton rearrangement, leading 
to different EMT of these cells and modulating the huMETCAM/MUC18-mediated 
tumor progression and metastasis. Different intrinsic cofactors in different cancer 
cell lines may modulate METCAM/MUC18 and alter cell-to-cell and cell-extracellular 
matrix interactions in the tumor microenvironment, resulting in affecting tumor pro-
gression and metastasis in vivo. Finally, these cofactors/ligands may interact differ-
ently with METCAM/MUC18 in different cell lines and affect other host physiological 
factors, which may augment or suppress in vivo tumor progression and metastasis by 
affecting metabolic switch, pro-apoptosis/anti-apoptosis, tumor angiogenesis, and 
host immune system in the tumor micro-milieu and in various metastatic sites [17, 37, 
40, 111, 112]. Thus, the identification of the cofactors and the huMETCAM/MUC18-
cognate heterophilic ligand(s) is critical for understanding the mechanism.
6. Conclusions
METCAM/MUC18 also plays a key positive function in the progression of angio-
sarcoma, breast cancer, gastric cancer, glioblastoma, hepatocellular carcinoma, 
lung cancer, melanoma, NPC type III, osteosarcoma, pancreatic cancer, prostate 
cancer, and possibly other cancers. On the other hand, METCAM/MUC18 plays a 
key role in suppressing the progression of colorectal cancer, one mouse melanoma 
cell line, NPC type I, ovarian cancer, pancreatic cancer, prostate cancer PC-3 cell 
line, and perhaps hemangioma. To further understand its role in these processes, 
it is essential to further identify its cofactor regulators and cognate heterophilic 
ligands, define its functional domains, and study its cross talk with members of 
various signal transduction pathways, the regulation of its expression at the level of 
transcription, and effects of N-glycosylation on the functions of the protein.
7. Research perspectives and clinical applications
7.1 Research perspectives
The current studies have laid an important foundation for future intriguing investi-
gation to further understand the detailed mechanism of METCAM/MUC18-mediated 
tumor progression and metastasis of various cancer cell lines. For this purpose besides 
those have been described above, other future endeavors may include (a) under-
standing the mechanisms in the METCAM/MUC18-mediated tumor progression 
and metastasis, such as intrinsic growth capability, key chemokines and cytokines 
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participating in the evasion of immunological responses, and key pro-angiogenic and 
anti-angiogenic factors participating in the augmentation of angiogenesis, (b) identifi-
cation of possible miRNAs and noncoding RNAs participating in the process upstream 
and downstream of METCAM/MUC18 [126], and (c) possible clinical applications 
that should be explored. Precaution should be taken that a thorough picture may be 
possibly revealed only after the comprehensive studies are successfully executed.
7.2 Clinical applications
Four major approaches may be taken to decrease or stop the progression and 
metastatic propensity of cancer cells and keep them staying at the primary site, stop-
ping them in a dormant state or keeping the disseminating cancer cells at the state of 
micrometastases: (a) Dispense humanized anti-METCAM/MUC18 antibodies to the 
cancer patients [125]. (b) Knocking down the METCAM/MUC18 expression by siR-
NAs to silence the genes [35, 36]. For knocking down therapy, the METCAM/MUC18 
gene-specific siRNAs may be delivered by liposomes or other delivery methods [126]. 
(c) Target at downstream key members in the signaling pathways which are activated 
by the promotion. (d) Target at the cofactors or the cognate heterophilic ligand(s) of 
METCAM/MUC18. The above strategies may be used in single or better in combina-
tion for treating the patients. However, the dual role of METCAM/MUC18 in cancer 
progression may limit the above clinical applications to only cancers exhibiting a 
positive METCAM/MUC18-mediated tumor progression and metastasis.
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